Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases
Key facts
- Who runs it
- University Hospital Heidelberg
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 90 people, planned
- Started
- 1 Feb 2024
- Expected to end
- 1 May 2029
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Preoperative Radiotherapy
- Intraoperative Radiation
- Postoperative Radiotherapy
- Record updated
- 27 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Histologically confirmed solid malignancy; Metastatic brain disease (1-10 brain metastases), with at least one brain metastasis in a non-eloquent location (i.e. motor or speech) planned for resection; Maximum size of the brain metastasis <5cm; Eligibility of patients for both stereotactic radiotherapy and resection; Time interval from resection to adjuvant stereotactic radiosurgery of 2-6 weeks; Time interval from neoadjuvant stereotactic radiosurgery to resection of 1-7 days; Possibility to postpone resection for neoadjuvant stereotactic radiosurgery, if applicable; Karnofsky performance scores >= 70 or Eastern Cooperative Oncology Group (ECOG) >= 2 at enrollment; Age ≥ 18 years of age; For women with childbearing potential, (and men) adequate contraception; Ability of subject to understand character and individual consequences of the clinical trial; Written informed consent (must be available before enrolment in the trial)
Who cannot take part
- Necessity of immediate surgical resection due to life threatening symptoms
- Previous radiotherapy of the brain
- Small-cell lung cancer (SCLC) or hematologic malignancy as primary malignant illness
- Leptomeningeal disease suspected RadCav Trial Protocol Version 1.1, 01.07.2022 18
- brain metastasis directly located (≤10mm) next to the optic system or brain stem
- Refusal of the patients to take part in the study
- Contraindication for contrast-enhanced MRI
- Pregnant or lactating women
- Participation in another competing clinical study or observation period of competing trials, respectively
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients suffering from malignancies in advanced stages often develop brain metastases, which limit both the life span and the quality of life.
Read full original descriptionShow less
Combining surgery and radiotherapy for resectable brain metastases is standard of care but there is a lot of controversy on which kind of radiotherapy is best suitable. Recently, first volumetric in-silico analyses point to theoretical advantages of neoadjuvant stereotactic radiotherapy of brain metastases. Special about this trial is the direct comparison between the three currently discussed radiotherapy options for resectable brain metastases: Neoadjuvant stereotactic radiotherapy, intraoperative radiotherapy and adjuvant stereotactic radiotherapy.
The 3 groups in the trial
- Experimental Arm A (Preoperativ SRS)Treatment being tested
Preoperative stereotatic radiosurgery following resection of brain metastases after 1-7 days
Treatment: Preoperative Radiotherapy
- Experimental Arm B (Intraoperativ SRS)Treatment being tested
Intraoperative stereotactic radiotherapy after resection of brain metastases
Treatment: Intraoperative Radiation
- Standard Treatment Arm C (Posoperativ SRS)Existing treatment, for comparison
Resection of brain metastases following stereotactic radiotherapy after 2-6 weeks
Treatment: Postoperative Radiotherapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases - A Prospective Randomized Explorative Phase II Trial
- Record updated
- 27 May 2026